Advertisement
ALNY vs PHAT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a StrongBuy and PHAT is a StrongBuy.
Momentum Indicator for ALNY turns positive, indicating new upward trend
ALNY saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In 66 of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, 18 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for ALNY just turned positive on October 16, 2026. Looking at past instances where ALNY's MACD turned positive, the stock continued to rise in 33 of 47 cases over the following month. The odds of a continued upward trend are 70%.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 219 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 65 cases where ALNY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ALNY entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.459) is normal, around the industry mean (2.973). P/E Ratio (38.719) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
PHAT's RSI Indicator ascending out of oversold territory
The RSI Oscillator for PHAT moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 62 cases where PHAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for PHAT just turned positive on October 08, 2026. Looking at past instances where PHAT's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in 242 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In 62 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for PHAT entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.647) is normal, around the industry mean (2.973). P/E Ratio (-5.608) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (2.511) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALNY | PHAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 89 | 100 | |
SMR RATING 1..100 | 14 | 100 | |
PRICE GROWTH RATING 1..100 | 78 | 82 | |
P/E GROWTH RATING 1..100 | 96 | 14 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PHAT's Valuation (17) in the null industry is significantly better than the same rating for ALNY (94) in the Biotechnology industry. This means that PHAT’s stock grew significantly faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as PHAT (100) in the null industry. This means that ALNY’s stock grew similarly to PHAT’s over the last 12 months.
ALNY's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for PHAT (100) in the null industry. This means that ALNY’s stock grew significantly faster than PHAT’s over the last 12 months.
ALNY's Price Growth Rating (78) in the Biotechnology industry is in the same range as PHAT (82) in the null industry. This means that ALNY’s stock grew similarly to PHAT’s over the last 12 months.
PHAT's P/E Growth Rating (14) in the null industry is significantly better than the same rating for ALNY (96) in the Biotechnology industry. This means that PHAT’s stock grew significantly faster than ALNY’s over the last 12 months.
| ALNY | PHAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 85% |
| Advances ODDS (%) | 8 days ago 73% | 3 days ago 84% |
| Declines ODDS (%) | 2 days ago 68% | 1 day ago 87% |
| BollingerBands ODDS (%) | 1 day ago 69% | N/A |
| Aroon ODDS (%) | 1 day ago 75% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green while PHAT’s FA Score has 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- PHAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 5 TA indicator(s) are bullish while PHAT’s TA Score has 6 bullish TA indicator(s).
- ALNY’s TA Score: 5 bullish, 5 bearish.
- PHAT’s TA Score: 6 bullish, 2 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -2.88% price change this week, while PHAT (@Biotechnology) price change was -5.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
ALNY is expected to report earnings on Oct 29, 2026.
PHAT is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PHAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with ALNY. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then ALNY could also see price increases.
| Ticker / NAME | Correlation To PHAT | 1D Price Change % | ||
|---|---|---|---|---|
| PHAT | 100% | -0.28% | ||
| ALNY - PHAT | 45% Loosely correlated | +0.97% | ||
| QCLS - PHAT | 39% Loosely correlated | +3.50% | ||
| ATRA - PHAT | 36% Loosely correlated | +0.86% | ||
| KURA - PHAT | 32% Poorly correlated | -0.20% | ||
| STOK - PHAT | 32% Poorly correlated | +0.08% | ||
More | ||||